EXCLUSIVE: Alzamend Neuro To Launch Phase 2 Study For Lead Drug For PTSD Patients In Late 2025 To Assess Lithium Delivery Benefits
Alzamend Neuro plans a Phase 2 trial of AL001 for PTSD in late 2025, aiming for better lithium delivery, improved safety, and ...
Hosted on MSN7mon
EXCLUSIVE: Alzamend Neuro To Assess AL001 Alzheimer's Candidate Against Commonly Marketed Lithium Salt In Phase 2 Head-To-Head Study
Alzamend says that this study will assist ... at a lithium carbonate equivalent dose of 240 mg 3 times daily, is designed to be unlikely to require lithium therapeutic drug monitoring (TDM).
EXCLUSIVE: Alzamend Neuro To Start First Phase 2 Study For Lead Candidate In 2025
Alzamend Neuro will begin its first Phase 2 trial of AL001 in 2025, using advanced imaging to study lithium distribution and optimize treatment efficacy.
Monthly Prescribing Reference13y
Lithium Carbonate Tablets
Lithium carbonate 300mg; scored tabs. Risk of lithium toxicity (esp. recent febrile illness, acute ingestion, volume depletion/dehydration, impaired renal function, cardiovascular disease ...
Hosted on MSN1y
Side Effects
Lithium carbonate is a prescription medicine used in the treatment of bipolar disorder and mania. It helps to decrease the abnormal and excessive activity of the nerve cells and calms the brain.
Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital
Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy human subjectsATLANTA ...